OptimizeRx Corp. announced its intention to appoint a new independent director to its Board of Directors during the second half of 2025. This initiative is part of the company's ongoing process to refresh and expand its board.
With this planned appointment, OptimizeRx will have added three new directors since 2020, including Catherine Klema in 2024 and Gregory D. Wasson in 2020. The company's current board consists of five directors.
The Board is seeking an individual with relevant expertise and experience to complement existing members and further the execution of the company’s strategy and value creation plans. This move aims to enhance the board's depth and breadth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.